Consistent with the lower malignant evolution, compared to WT AML cells, a significantly lower mutation burden was observed in ATG4B‐deficient AML cells after serial transplantation, as demonstrated by the lower frequencies of insertions/deletions and copy number variations in ATG4B‐deficient AML cells (Figure S6J, Supporting Information). The gene discussed is ATG4B; the disease is acute myeloid leukemia.